NDC 79952-110

ZYNLONTA

Loncastuximab Tesirine

ZYNLONTA is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Adc Therapeutics America, Inc.. The primary component is Loncastuximab Tesirine.

Product ID79952-110_d6c238f0-d15b-4374-a802-2344c38422e5
NDC79952-110
Product TypeHuman Prescription Drug
Proprietary NameZYNLONTA
Generic NameLoncastuximab Tesirine
Dosage FormInjection, Powder, Lyophilized, For Solution
Route of AdministrationINTRAVENOUS
Marketing Start Date2021-04-30
Marketing CategoryBLA /
Application NumberBLA761196
Labeler NameADC Therapeutics America, Inc.
Substance NameLONCASTUXIMAB TESIRINE
Active Ingredient Strength5 mg/mL
NDC Exclude FlagN
Listing Certified Through2022-12-31

Packaging

NDC 79952-110-01

1 VIAL, SINGLE-DOSE in 1 CARTON (79952-110-01) > 10 mL in 1 VIAL, SINGLE-DOSE
Marketing Start Date2021-04-30
NDC Exclude FlagN
Sample Package?N

Drug Details


Trademark Results [ZYNLONTA]

Mark Image

Registration | Serial
Company
Trademark
Application Date
ZYNLONTA
ZYNLONTA
88506358 not registered Live/Pending
ADC Therapeutics SA
2019-07-09

© 2021 FDA.report
This site is not affiliated with or endorsed by the FDA.